Fatigue News and Research

RSS

Pemetrexed, paclitaxel regimens equally effective in NSCLC

PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

New guide offers employers online and interactive toolkit to help support employees with cancer

A new guide developed by The National Business Group on Health and the National Comprehensive Cancer Network offers employers an online and interactive toolkit to help address the growing impact of cancer in the workplace.

6 Dec 2013

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Boston Scientific Corporation and The Medicines Company announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System.

6 Dec 2013

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

New report on global prevalence of anemia

Despite increasing efforts to diagnose and treat anemia worldwide, there remains a surprisingly large global burden of the disease, particularly among young children and women, according to a new report on trends in anemia between 1990 and 2010.

3 Dec 2013

Viewpoints: Where's Obama's 'Mission Accomplished' banner?; health law critics overlooking those denied affordable care in the past

Great news: The White House says that Healthcare.gov and the 36 federally run insurance exchanges are finally good to go. The only thing missing from Sunday's relentlessly upbeat progress report was President Obama in front of a "Mission Accomplished" banner. Sunday's eight-page report was intended to meet Mr. Obama's deadline for fixing the site after its October 1 debut was a calamity. But the more important goal was political -- namely, claiming enough progress to prevent Democrats on Capitol Hill from joining the GOP demand for delaying the individual mandate to buy insurance or even the entire program (12/1).

3 Dec 2013

Four-drug regimen shows first-line efficacy in advanced NSCLC

A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report.

2 Dec 2013

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

People living with chronic fatigue are set to benefit with the opening next week (Dec 2), of the National Centre for Neuroimmunology and Emerging Diseases at Griffith University.

30 Nov 2013

Senior patients with traumatic injuries can benefit from geriatric care

Older patients who received extra geriatric care following a traumatic injury were able to return to roughly two thirds more daily activities than those without a consultation, according to a new study led by researchers from the University of Michigan Health System and University of California, Los Angeles.

28 Nov 2013

Modafinil in combination with antidepressants reduces severity of depression more effectively

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

28 Nov 2013

Researchers show benefits from testosterone administration in hysterectomized women

Hysterectomy and oophorectomy (the removal of ovaries) are performed to treat various diseases in women, including cancer. These procedures are accompanied not only by a decline in estrogen but also testosterone levels in the blood.

27 Nov 2013

Researchers develop prototype spacesuit biosensors to monitor astronauts' health

Kansas State University researchers are improving astronauts' outerwear for outer space. The collaborative team -- which includes electrical and computer engineering professors and more than a dozen students -- envisions a future spacesuit that could monitor astronauts' health and use body heat to power electronics.

27 Nov 2013

Survivors of hematopoietic stem cell transplant benefit from expressive helping

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

27 Nov 2013

Fatigue News and Research

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

New guide offers employers online and interactive toolkit to help support employees with cancer

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

College students not only bring dirty socks but also mononucleosis to home

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

New report on global prevalence of anemia

Viewpoints: Where's Obama's 'Mission Accomplished' banner?; health law critics overlooking those denied affordable care in the past

Four-drug regimen shows first-line efficacy in advanced NSCLC

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

Senior patients with traumatic injuries can benefit from geriatric care

Modafinil in combination with antidepressants reduces severity of depression more effectively

Researchers show benefits from testosterone administration in hysterectomized women

Researchers develop prototype spacesuit biosensors to monitor astronauts' health

Survivors of hematopoietic stem cell transplant benefit from expressive helping

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News